StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3039% above fair value
$0.54+0.01 (+2.66%)

Close on Nov 16, 2026Market cap $75.32MP/E –Yield –

Rani Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Rani Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $29.38M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$24.61M-16.2%
FY2023Dec 31, 2023$29.38M+0.8%
FY2022Dec 31, 2022$29.15M–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$3.77M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$13.54M-52.2%
Q2 FY2025Jun 30, 2025$17.23M-41.6%
Q1 FY2025Mar 31, 2025$20.92M-28.9%
Q4 FY2024Dec 31, 2024$24.61M-16.2%
Q3 FY2024Sep 30, 2024$28.31M-3.5%
Q2 FY2024Jun 30, 2024$29.50M+0.8%
Q1 FY2024Mar 31, 2024$29.44M+0.8%
Q4 FY2023Dec 31, 2023$29.38M+0.8%
Q3 FY2023Sep 30, 2023$29.32M+108.1%
Q2 FY2023Jun 30, 2023$29.27M–
Q1 FY2023Mar 31, 2023$29.21M–
Q4 FY2022Dec 31, 2022$29.15M+650.5%
Q3 FY2022Sep 30, 2022$14.09M+273.7%
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$3.88M–
Q4 FY2020Dec 31, 2020$3.77M–

More Rani Therapeutics figures

See a number that looks wrong?